Panelists discuss how classifying EGFR mutations into molecular subgroups, including PACC, refines diagnosis and informs targeted treatment decisions.
Back
Navigating Advances in NSCLC With EGFR PACC Mutations
Panelists discuss how evolving molecular classification, improved detection methods, and emerging data from novel tyrosine kinase inhibitors like firmonertinib are transforming the treatment of non–small cell lung cancer (NSCLC) with EGFR PACC mutations. They highlight a future where advanced sequencing and innovative therapeutic strategies will enable more precise, effective, and durable management of this complex molecular subset.
Navigating Advances in NSCLC With EGFR PACC Mutations
Episodes
All
All
Panelists discuss how advanced genomic profiling techniques are vital for accurate detection of PACC mutations.
Panelists discuss how current TKI therapies offer limited efficacy for PACC mutations, necessitating individualized and trial-based approaches.
Panelists discuss how firmonertinib shows promise as a next-generation TKI with broad EGFR activity and favorable tolerability.
Panelists discuss how the FURTHER trial demonstrated firmonertinib’s efficacy and safety in patients with PACC mutations.
Panelists discuss how novel agents and emerging strategies may further optimize sequencing and outcomes for EGFR PACC-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Dr Viansone on ADC Sequencing in Metastatic HER2+ Breast Cancer
5